$53.95
-1.85-3.32%
Last update: Nov 10, 3:02 PM
Genmab AS
GMABNASDAQ
The average analyst price target for Genmab is $47.50, 12.0% below the current price. Of 13 analysts, 13 rate it Buy. Targets range from $27 to $80. The latest change came on Oct 30, 2026, when Morgan Stanley raised its price target on Genmab from $42 to $57 and kept an Equal-Weight rating.
Price Target Range — 13 Quarters
Analyst Consensus — 13 Analysts
Rating Trend — Last 9 Months
